Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study
Background: Malignant phyllodes tumors (MPTs) with sarcomatous components are often associated with substantial risks for local and distant recurrences. A more comprehensive characterization of their clinicopathological features and molecular profiles may offer significant potential innovative thera...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332500049X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199456722616320 |
|---|---|
| author | Ting Lei Yunjie Song Zhiyi Shen Yongqiang Shi Cunyan Xia Xu Deng Wenyue Da Yan Peng Qing Li |
| author_facet | Ting Lei Yunjie Song Zhiyi Shen Yongqiang Shi Cunyan Xia Xu Deng Wenyue Da Yan Peng Qing Li |
| author_sort | Ting Lei |
| collection | DOAJ |
| description | Background: Malignant phyllodes tumors (MPTs) with sarcomatous components are often associated with substantial risks for local and distant recurrences. A more comprehensive characterization of their clinicopathological features and molecular profiles may offer significant potential innovative therapeutic strategies. Methods: A total of ten cases were collected with eight cases undergoing DNA next-generation sequencing (NGS). The clinicopathological characteristics, prognostic information, and genomic profiles were compared to those of MPTs without sarcomatous components. Results: Compared to MPT without sarcomatous components, no significant differences were found in age, tumor position, tumor size, menopausal status, or presence of fibroadenoma (p > 0.05). MPTs with osteosarcoma components had a poor prognosis either compared with other sarcomatous components (p = 0.027) or MPTs without sarcomatous components (p = 0.033). A notably high frequency of mutations was observed in several key genes within MPTs exhibiting sarcomatous components: TP53 (n = 6, 75.0 %), MUC16 (n = 4, 50.0 %), PTCH1 (n = 3, 37.5 %), and APC (n = 3, 37.5 %). In MPTs characterized by sarcomatous components, MCL1 (n = 6, 75.0 %) and MYC (n = 5, 62.5 %) demonstrated a notably high frequency of amplification. The NOTCH signaling pathway was significantly associated with MPTs characterized by sarcomatous components (13.6 % vs 75.0 %, p = 0.001). Conclusions: The presence of an osteosarcoma component may serve as an indicator for unfavorable prognosis. Activating mutations in TP53 have been identified in these tumors. Furthermore, it typically facilitates tumor formation and progression via the NOTCH signaling pathway. These findings may offer valuable insights for clinical prognosis and identify potential therapeutic targets. |
| format | Article |
| id | doaj-art-d99a32362e85462c8aca27ed10dd89be |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-d99a32362e85462c8aca27ed10dd89be2025-02-08T05:00:06ZengElsevierTranslational Oncology1936-52332025-03-0153102318Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular studyTing Lei0Yunjie Song1Zhiyi Shen2Yongqiang Shi3Cunyan Xia4Xu Deng5Wenyue Da6Yan Peng7Qing Li8Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaJiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug DevelopmentDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR ChinaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR China; Corresponding author at: Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, PR China.Background: Malignant phyllodes tumors (MPTs) with sarcomatous components are often associated with substantial risks for local and distant recurrences. A more comprehensive characterization of their clinicopathological features and molecular profiles may offer significant potential innovative therapeutic strategies. Methods: A total of ten cases were collected with eight cases undergoing DNA next-generation sequencing (NGS). The clinicopathological characteristics, prognostic information, and genomic profiles were compared to those of MPTs without sarcomatous components. Results: Compared to MPT without sarcomatous components, no significant differences were found in age, tumor position, tumor size, menopausal status, or presence of fibroadenoma (p > 0.05). MPTs with osteosarcoma components had a poor prognosis either compared with other sarcomatous components (p = 0.027) or MPTs without sarcomatous components (p = 0.033). A notably high frequency of mutations was observed in several key genes within MPTs exhibiting sarcomatous components: TP53 (n = 6, 75.0 %), MUC16 (n = 4, 50.0 %), PTCH1 (n = 3, 37.5 %), and APC (n = 3, 37.5 %). In MPTs characterized by sarcomatous components, MCL1 (n = 6, 75.0 %) and MYC (n = 5, 62.5 %) demonstrated a notably high frequency of amplification. The NOTCH signaling pathway was significantly associated with MPTs characterized by sarcomatous components (13.6 % vs 75.0 %, p = 0.001). Conclusions: The presence of an osteosarcoma component may serve as an indicator for unfavorable prognosis. Activating mutations in TP53 have been identified in these tumors. Furthermore, it typically facilitates tumor formation and progression via the NOTCH signaling pathway. These findings may offer valuable insights for clinical prognosis and identify potential therapeutic targets.http://www.sciencedirect.com/science/article/pii/S193652332500049XMalignant phyllodes tumorSarcomatous componentOsteosarcoma componentsTP53NOTCH pathway |
| spellingShingle | Ting Lei Yunjie Song Zhiyi Shen Yongqiang Shi Cunyan Xia Xu Deng Wenyue Da Yan Peng Qing Li Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study Translational Oncology Malignant phyllodes tumor Sarcomatous component Osteosarcoma components TP53 NOTCH pathway |
| title | Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study |
| title_full | Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study |
| title_fullStr | Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study |
| title_full_unstemmed | Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study |
| title_short | Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study |
| title_sort | malignant phyllodes tumors with sarcomatous components a histopathologic and molecular study |
| topic | Malignant phyllodes tumor Sarcomatous component Osteosarcoma components TP53 NOTCH pathway |
| url | http://www.sciencedirect.com/science/article/pii/S193652332500049X |
| work_keys_str_mv | AT tinglei malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT yunjiesong malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT zhiyishen malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT yongqiangshi malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT cunyanxia malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT xudeng malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT wenyueda malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT yanpeng malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy AT qingli malignantphyllodestumorswithsarcomatouscomponentsahistopathologicandmolecularstudy |